100% Quality Guarantee
PhD-Level Technical Support
Key Features

Gemtuzumab Biosimilar (CD33) Antibody (HDBS0015)

SKU HDBS0015
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein CD33
Reactivity Human
Host Species Chimeric Humanized
Isotype IgG4
$569

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Gemtuzumab Biosimilar (CD33) Antibody (HDBS0015)

The CD33 Gemtuzumab Ozogamicin Biosimilar Monoclonal Antibody (HDBS0015) is a cutting-edge product designed for research involving the CD33 protein, which is overexpressed in certain types of leukemia. This biosimilar monoclonal antibody is highly specific and reactive with samples from human origin, making it an ideal tool for studying the role of CD33 in cancer biology.Developed as a biosimilar to the original gemtuzumab ozogamicin antibody, this product offers researchers a reliable and validated reagent for use in various applications, including flow cytometry, immunohistochemistry, and ELISA.

By targeting the CD33 protein, this antibody enables precise detection and analysis of CD33 expression in cancer cells, providing valuable insights into disease mechanisms and potential therapeutic strategies.The CD33 Gemtuzumab Ozogamicin Biosimilar Monoclonal Antibody is a versatile tool for researchers working in the fields of oncology and immunotherapy. By understanding the functions and interactions of CD33 in leukemia cells, scientists can advance their knowledge of disease progression and develop more effective treatments for patients with CD33-positive leukemias.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose